Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Perry's liquidity event comes as the Arrowhead stock price surged.
Michael S. Perry, a Director at Arrowhead Pharmaceuticals, sold 11,600 shares of the company's common stock on August 18, 2026, according to an SEC Form 4 filing. The transaction's value was calculated at $1 million based on a weighted average sale price of $87.30 per share. The post-transaction value, calculated using the market close price of $87.90 per share, amounted to $1,017,900.
Arrowhead Pharmaceuticals, a clinical-stage biopharmaceutical company founded in 1989 and headquartered in Pasadena, California, has a market capitalization of $12.2 billion and employs 711 people. The company specializes in RNAi-based therapeutics, an innovative approach to treating genetic and metabolic disorders that currently lack effective treatment options.
Arrowhead Pharmaceuticals generated $669.5 million in revenue during the trailing twelve months (TTM) period and continues to invest in its pipeline of potential treatments. Despite the capital-intensive nature of biopharmaceutical development, the company remains optimistic about the potential success and commercialization of its clinical candidates, which could generate significant value for shareholders.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
